Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

40 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23.8M shares of 53.5M outstanding shares and own 44.47% of the company stock.
Largest 10 shareholders include GILEAD SCIENCES, INC. (9.11M shares), Bain Capital Life Sciences Investors, LLC (4.57M shares), Merck & Co., Inc. (1.48M shares), TAKEDA PHARMACEUTICAL CO LTD (1.48M shares), MORGAN STANLEY (1.44M shares), Ghisallo Capital Management LLC (1.33M shares), VANGUARD GROUP INC (1.15M shares), AJU IB Investment Co., Ltd. (668K shares), FMR LLC (512K shares), and GEODE CAPITAL MANAGEMENT, LLC (370K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.